L-DOPA-2,5,6-d<sub>3</sub>|cas:53587-29-4|西域试剂

L-DOPA-2,5,6-d₃,99.95%

产品编号：Bellancom-132392S| CAS NO：53587-29-4| 分子式：C₉H₈D₃NO₄| 分子量：200.21

左旋多巴-2,5,6-d3（左旋多巴-2,5,6-d3）是氘标记的左旋多巴。左旋多巴（左旋多巴）是神经递质多巴胺的口服活性代谢前体。左旋多巴能穿过血脑屏障，在大脑中转化为多巴胺。

本网站销售的所有产品仅用于工业应用或者科学研究等非医疗目的,不可用于人类或动物的临床诊断或者治疗,非药用,非食用，

货号	价格	库存与货期
Bellancom-132392S	￥1900.00	杭州北京（现货）
Bellancom-132392S	￥3100.00	杭州北京（现货）
Bellancom-132392S	￥4900.00	杭州北京（现货）

增值税发票√顺丰快递√订货电话：18601927057

L-DOPA-2,5,6-d₃

产品介绍

L-DOPA-2,5,6-d₃ 是 L-DOPA 的氘代物。L-DOPA (Levodopa) 是具有口服活性的神经递质多巴胺的代谢前体。L-DOPA 可以透过血脑屏障，并在大脑中转化为多巴胺。L-DOPA 具有抗痛觉过敏作用，并有研究帕金森氏病的潜力。

生物活性

L-DOPA-2,5,6-d₃ is the deuterium labeled L-DOPA. L-DOPA (Levodopa) is an orally active metabolic precursor of neurotransmitters dopamine. L-DOPA can cross the blood-brain barrier and is converted into dopamine in the brain.

体外研究

Stable heavy isotopes of hydrogen, carbon, and other elements have been incorporated into drug molecules, largely as tracers for quantitation during the drug development process. Deuteration has gained attention because of its potential to affect the pharmacokinetic and metabolic profiles of drugs.

西域 has not independently confirmed the accuracy of these methods. They are for reference only.

体内研究

性状

Solid

溶解性数据

In Vitro:

H₂O : 25 mg/mL (124.87 mM; ultrasonic and warming and adjust pH to 1 with HCl and heat to 60°C)

配制储备液

浓度溶剂体积质量	1 mg	5 mg	10 mg

1 mM	4.9948 mL	24.9738 mL	49.9476 mL
5 mM	0.9990 mL	4.9948 mL	9.9895 mL
10 mM	0.4995 mL	2.4974 mL	4.9948 mL

请根据产品在不同溶剂中的溶解度选择合适的溶剂配制储备液；一旦配成溶液，请分装保存，避免反复冻融造成的产品失效。
储备液的保存方式和期限：-80°C, 6 months; -20°C, 1 month。-80°C 储存时，请在 6 个月内使用，-20°C 储存时，请在 1 个月内使用。

运输条件

Room temperature in continental US; may vary elsewhere.

储存方式

Powder	-20°C	3 years
	4°C	2 years
In solvent	-80°C	6 months
	-20°C	1 month

参考文献

. Russak EM, et al. Impact of Deuterium Substitution on the Pharmacokinetics of Pharmaceuticals. Ann Pharmacother. 2019;53(2):211-216. [Content Brief]

. Hyland K, et al. Aromatic L-amino acid decarboxylase deficiency: diagnostic methodology. Clin Chem. 1992 Dec;38(12):2405-10. [Content Brief]

. Merims D, et al. Dopamine dysregulation syndrome, addiction and behavioral changes in Parkinson's disease. Parkinsonism Relat Disord. 2008;14(4):273-80. Epub 2007 Nov 7. [Content Brief]

[4]. Perez-Pardo P, et al. Additive Effects of Levodopa and a Neurorestorative Diet in a Mouse Model of Parkinson's Disease. Front Aging Neurosci. 2018 Aug 3;10:237. [Content Brief]

[5]. Park HJ, et al. Anti-allodynic effects of levodopa in neuropathic rats. Yonsei Med J. 2013 Mar 1;54(2):330-5. [Content Brief]

化学品安全说明书(MSDS)

下载MSDS

质检证书(COA)

产品编号(Item Number)

批号(Lot Number)

相关产品

符号	GHS07
信号词	Warning
危害声明	H302-H315-H319-H335
警示性声明	P261-P305 + P351 + P338
个人防护装备	dust mask type N95 (US);Eyeshields;Gloves
危害码 (欧洲)	Xn
风险声明 (欧洲)	R22
安全声明 (欧洲)	26-36
危险品运输编码	NONH for all modes of transport

[1]. Russak EM, et al. Impact of Deuterium Substitution on the Pharmacokinetics of Pharmaceuticals. Ann Pharmacother. 2019;53(2):211-216.

[2]. Hyland K, et al. Aromatic L-amino acid decarboxylase deficiency: diagnostic methodology. Clin Chem. 1992 Dec;38(12):2405-10.

[3]. Merims D, et al. Dopamine dysregulation syndrome, addiction and behavioral changes in Parkinson's disease. Parkinsonism Relat Disord. 2008;14(4):273-80. Epub 2007 Nov 7.

[4]. Perez-Pardo P, et al. Additive Effects of Levodopa and a Neurorestorative Diet in a Mouse Model of Parkinson's Disease. Front Aging Neurosci. 2018 Aug 3;10:237.

[5]. Park HJ, et al. Anti-allodynic effects of levodopa in neuropathic rats. Yonsei Med J. 2013 Mar 1;54(2):330-5.

L-DOPA-2,5,6-d3,99.95%

L-DOPA-2,5,6-d3

化学品安全说明书(MSDS)

质检证书(COA)

在线咨询

L-DOPA-2,5,6-d₃,99.95%

L-DOPA-2,5,6-d₃